Monte Rosa Therapeutics, Inc. Financing Cash Flow
Monte Rosa Therapeutics, Inc. (GLUE) reported Financing Cash Flow of $331.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.21M, a 779.73% increase year-over-year.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $328.33M, a 2345150.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $29.62M, a 4772.37% increase year-over-year.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $348.00K, a 2220.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $30.35M, a 69.31% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $98.89M, a 259.71% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $27.49M, a 34.33% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $20.47M, a 94.58% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $331.55M 10-Q · filed 2026-08-06 | $361.17M derived: sum of 3 quarters · filed 2026-08-06 | $361.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $328.33M 10-Q · filed 2026-05-07 | $357.96M derived: sum of 2 quarters · filed 2026-05-07 | $358.31M derived: sum of 3 quarters · filed 2026-05-07 | $358.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $29.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $29.97M derived: sum of 2 quarters · filed 2026-03-17 | $30.34M derived: sum of 3 quarters · filed 2026-08-06 | $30.35M 10-K · filed 2026-03-17 |
| 2025-09-30 | $348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $713.00K derived: sum of 2 quarters · filed 2026-08-06 | $727.00K 10-Q · filed 2025-11-06 | $1.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $379.00K 10-Q · filed 2026-08-06 | $987.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-07 | $622.00K derived: sum of 2 quarters · filed 2026-05-07 | $637.00K derived: sum of 3 quarters · filed 2026-05-07 | $98.66M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $608.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $623.00K derived: sum of 2 quarters · filed 2026-03-17 | $98.65M derived: sum of 3 quarters · filed 2026-03-17 | $98.89M 10-K · filed 2026-03-17 |
| 2024-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $98.04M derived: sum of 2 quarters · filed 2025-11-06 | $98.28M 10-Q · filed 2025-11-06 | $123.46M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $98.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $98.27M 10-Q · filed 2025-08-07 | $123.44M derived: sum of 3 quarters · filed 2025-08-07 | $124.54M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $246.00K 10-Q · filed 2025-05-08 | $25.42M derived: sum of 2 quarters · filed 2025-05-08 | $26.52M derived: sum of 3 quarters · filed 2025-05-08 | $27.72M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $25.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $26.27M derived: sum of 2 quarters · filed 2025-03-20 | $27.47M derived: sum of 3 quarters · filed 2025-03-20 | $27.49M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.30M derived: sum of 2 quarters · filed 2024-11-07 | $2.32M 10-Q · filed 2024-11-07 | $22.75M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.22M 10-Q · filed 2024-08-08 | $21.65M derived: sum of 3 quarters · filed 2024-08-08 | $21.43M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $18.00K 10-Q · filed 2024-05-09 | $20.45M derived: sum of 2 quarters · filed 2024-05-09 | $20.23M derived: sum of 3 quarters · filed 2024-05-09 | $20.33M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $20.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $20.22M derived: sum of 2 quarters · filed 2024-03-14 | $20.31M derived: sum of 3 quarters · filed 2024-03-14 | $20.47M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$121.00K derived: sum of 2 quarters · filed 2023-11-09 | $32.00K 10-Q · filed 2023-11-09 | -$103.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $249.00K 10-Q · filed 2023-08-10 | $114.00K derived: sum of 3 quarters · filed 2023-08-10 | $29.57M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $153.00K 10-Q · filed 2023-05-11 | $18.00K derived: sum of 2 quarters · filed 2023-05-11 | $29.47M derived: sum of 3 quarters · filed 2023-05-11 | $234.95M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $29.32M derived: sum of 2 quarters · filed 2023-03-16 | $234.79M derived: sum of 3 quarters · filed 2023-03-16 | $377.56M 10-K · filed 2023-03-16 |
| 2021-09-30 | $29.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $234.93M derived: sum of 2 quarters · filed 2022-11-10 | $377.70M 10-Q · filed 2022-11-10 | $377.69M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $205.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $348.24M 10-Q · filed 2022-08-11 | $348.23M derived: sum of 3 quarters · filed 2022-08-11 | $395.98M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $142.77M 10-Q · filed 2022-05-11 | $142.76M derived: sum of 2 quarters · filed 2022-05-11 | $190.51M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $47.74M derived: sum of 2 quarters · filed 2022-03-29 | $60.06M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $47.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $60.07M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $12.32M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |